Although asthma is a condition that is managed in the outpatient setting in most patients, the poorly control led and severe cases pose a major challenge to the health-care team. Recognition of the more common insidious and the less common rapid onset "acute asphyxic" asthma are important. The intensivist needs to be familiar with the factors that denote severity of the exacerbation. The management of respiratory failure in asthma, including pharmacologic and mechanical ventilation, are discussed in this article. Two important complications of the positive-pressure ventilation, the dynamic hyperinflation and barotrauma, may be life threatening. Interventions with helium-oxygen mixtures, anesthesia, and paralysis may be considered in certain situations.
Introduction lion)
. [2] Although in 1978-1989 there was a near-douAsthma is a chronic inflammatory disease of the air-bling in asthma mortality rates in the US, reaching 5000 ways. Patients with asthma are predisposed for devel-deaths per year, [3] a more recent study showed that in oping exacerbations, leading to respiratory failure. Rec-1995 Rec- -2002 age-adjusted asthma mortality has declined ognizing patients at risk, careful assessment, and rapid by 22.2-38.4%. Age-adjusted asthma hospitalization has institution of appropriate treatment is of paramount im-also significantly declined over the last decade. [4] None portance for favorable outcome. In this paper, we will theless, asthma still poses significant burden on health review the management of patients presenting with se-care resources, accounting for 1.8 million emergency vere asthma and respiratory failure. room visits, 500,000 hospitalizations, and 5000 deaths yearly in the US. [5] Although the rate of intensive-careEpidemiology unit (ICU) admissions is declining, approximately 4-7% Asthma affects 100-150 million people worldwide. It of patients admitted to the hospital with asthma may re accounts for 180,000 deaths annually. In India, it is esti-quire ICU care. [6] The total estimated cost of asthma in mated that approximately 15-20 million people are af-1994 was $5.8 billion, with hospitalization accounting fected. [1] In 2002, the overall prevalence of lifetime for more than half of all expenditures. It was also esti asthma in the United States was 11.9% (N = 24.7 mil-mated that 80% of resources were used by 20% of af fected population (defined as "high-cost patients"). [7] from the outset or continues to worsen despite institu tion of conventional therapy, leading to respiratory fail ure and death. Near-fatal asthma was described in 1991 by Molfino as being a patient with an acute asthma at tack of sudden onset, rapidly progressive, with extreme hypercapnea, and hypoxemia leading to a respiratory arrest. It was determined that the near-fatal nature of the attack was owing to the severe asphyxia rather than cardiac arrythmias. [8] Sudden ashpyxic asthma was rec ognized by Wasserfallen as a group of patients present ing with rapid decompensation, with occurrence of en dotracheal intubation in less than 3 h of onset of symp toms. [9] Robin, in 1989, described the course of four pa tients with acute fatal asthma, in which respiratory fail ure and death occurred within minutes of being symp tom-free. [10] Presentation Two distinct presentations of acute, severe deteriora tion of asthma are described in Table 1 . The first group of patients has a slow onset of the acute deterioration, with progression over hours to days to even weeks. This group comprises 80-90% of patients presenting to the Emergency Department (ED). Those patients have more airway inflammation; the inflammation is characterized by predominance of eosinophils, is more frequently trig gered by upper respiratory airway infections, and is slow to respond to therapy. The other group of patients termed asphyxic or hyperacute asthma, present with sudden onset, rapid progression (3-6 h from the onset of symp toms), is triggered by allergens, exercise, and physiologi cal stress, and usually responds rapidly to therapy. Those patients are thought to have a bronchospatic mecha nism of deterioration and usually have a predominance of neutrophils in the airways rather than eosinophils. [6] Initial Evaluation and Assessment of Asthma Severity
On presentation of the patient, a brief history and physi cal examination should be performed to assess imme diate needs. Several factors have been identified to pre dict mortality from asthma. These include history of prior sudden severe exacerbations, prior endotracheal intubations, prior ICU admissions, increased use of short acting β 2 -agonists (SABAs), and current or recent with drawal of systemic steroid use. A list of risk factors for asthma death is shown in Table 2 . [11] Patients with risk factors of asthma deaths should receive prompt and aggressive management. During the initial survey, sev eral features in the history and physical examination may help the physician in assessing the severity of the asth matic attack. These include the level of breathlessness, alteration in mental status, alterations in heart rate, res piratory rate, presence or absence of wheezing, use of accessory muscles, and presence of pulsus paradoxus. [11] A classification of the severity of asthma exacerbation is detailed in Table 3 . Some of the features are suggestive of imminent need for assisted ventila tion; these include cyanosis, inability to speak more than few words, severe agitation or confusion, absence of wheezing, or weak respiratory efforts, suggestive of muscle fatigue. Presence of these features should prompt the institution of maximal therapy, including as sisted ventilation. It is important to note that the evalua tion of patients with asthmatic exacerbation should be dynamic, with repeated examination after each thera peutic intervention. Objective measurement of indices of ventilation and oxygenation is important both to es tablish a baseline and to monitor response to treatment. Peak expiratory flow rate (PEFR) measurement should be used in the emergency room to quantify airflow ob struction and to evaluate response to treatment. Oxy gen saturation measurement or blood-gas analysis may be of value to show evidence of hypoxemia and/or res piratory acidosis, indicating the presence of a severe asthmatic attack.
Initial Management of Patients not Requir ing Mechanical Ventilation
Oxygen Supplementation Correction of significant hypoxemia with supplemental oxygen is extremely important and is the first step in the management patients presenting with asthmatic exac erbation. Supplemental oxygen therapy should be started by prehospital providers. [11] It is recommended to pro vide O 2 to maintain O 2 saturation at SaO 2 >90% (>95% in pregnant patients and in patients with coexistent heart disease). Oxygen saturation should be monitored until response to bronchodilator therapy has occurred. [11] Inhaled Bronchodilator Therapy SABAs Inhaled SABAs remain the mainstay of therapy in pa tients presenting with an acute exacerbation of asthma. A variety of β 2 -selective SABAs are being used, includ ing albuterol (salbutamol), bitolterol, and pirbuterol. β 2-Selective agents are preferred owing to the reduced risk of cardiotoxicity at high doses when compared with non selective agents. [11] Inhaled SABA can be administered in frequent repetitive administrations or continuous nebulization (10-15 mg/h albuterol). A Cochrane review was performed and published in 2003, comparing inter mittent vs continuous β-agonists; 157 trials were included with a total of 461 patients studied. [12] Continuous β 2 agonist therapy was shown to reduce the overall admis sion to the hospital, with patients with severe airway obstruction benefiting the most. Improvement in pulmo nary function including FEV1 (forced expiratory volume in 1) and PEFR was greater in the continuous group. There were no significant differences in pulse rate, blood pres sure, incidence of tremor, and potassium concentration.
Inhaled SABA can be administered using either me ter-dose inhaler with spacer device or nebulizer. Sev eral studies have shown equivalence in the degree of bronchodilation achieved with the two methods. [13] [14] [15] The equivalent dose needed to achieve similar bronchodilation to a 2.5-mg nebulized albuterol is ap proximately 6-12 puffs. Some patient groups, including children, elderly, agitated patients, or patients with se vere asthma, may not be able to coordinate inhalation of the medication from an MDI (metered dose inhaler) and may require nebulization. [12] Racemic albuterol comprises two enantiomers, (R) albuterol and (S)-albuterol. The two enantiomers have different pharmacologic properties. Whereas (R) albuterol has bronchodilator properties, (S)-albuterol in animal models has been shown to cause increased air way responsiveness. [16] Recently, an (R)-stereoisomer of albuterol (levalbuterol) was approved for clinical use. Two prospective, randomized, controlled trials examined the clinical efficacy of levalbuterol in the treatment of acute asthma in the pediatric population as compared with racemic albuterol. [17, 18] Outcome measures exam ined included change in spirometric measurements, changes in physiologic parameters, frequency of hospi talization, and length of emergency room care. Both stud ies showed equivalence of both drugs. A single study of the use of levalbuterol in acute asthma in adults was identified. [19] Nowak et al. in this prospective, open-la bel, nonrandomized pilot study evaluated the efficacy of levalbuterol in acute asthma in 91 patients. Patients re ceiving levalbuterol had greater spirometric response when compared with albuterol at different doses. Fur ther studies are needed to elucidate a possible role for levalbuterol in the treatment of acute asthma especially owing to the greater cost of levalbuterol. Anticholinergics Although β 2 -agonists are the first-line bronchodilating agents in the treatment of an acute asthmatic exacerba tion, ipratropium bromide should be considered as an additive treatment. A meta-analysis examined the role of ipratropium bromide in the treatment of acute asthma in both adults and children. [20] There was a modest sta tistical improvement in airflow obstruction when ipratropium was added to β 2 -agonists. Although clinical outcomes were improved in children, this was not es tablished in adults. There was no attributable increase in side effects when ipratropium bromide was used in conjunction with albuterol. Because ipratropium provides improved bronchodilation without risk of adverse effects, it is recommended to be used in addition to albuterol in the treatment of acute asthma exacerbation. [11] Corticosteroids Systemic corticosteroids are recommended for most patients with acute exacerbation of asthma. [11] Systemic corticosteroids have been shown to cause significantly greater and more rapid resolution of airflow obstruction, [21] reduce the rate of admissions, as well as prevent re lapse in the outpatient treatment of asthma. [22] The opti mal dose of corticosteroids varies in different studies. Manser et al., in a recent Cochrane review, examined nine trials that included a total of 344 patients. They were not able to show any difference among the different doses of corticosteroids in acute asthma requiring hos pital admission. Lower doses of corticosteroids, such as less than or equal to 80 mg daily of methylprednisolone or less than or equal to 400 mg daily of hydrocortisone, appeared to be adequate for the initial treatment of an acute asthma exacerbation. [23] Oral administration of corticosteroids is as effective as and less invasive than intravenous administration, and therefore, is the pre ferred route of therapy. [11] Inhaled corticosteroids (ICS) have also been studied in the treatment of acute exacerbation of asthma. In seven trials that included a total of 376 patients; ICS was shown to reduce the rate of admission to the hospi tal. This was more evident in the subgroup of patients not receiving systemic steroids. ICS significantly im proved peak expiratory flow rates and FEV1. The treat ment was well tolerated, with few reported adverse side effects. A comparison of ICS to systemic steroids alone could not be made with the available data. [24] Methylxanthines Methylxanthines are generally not recommended as part of the management of patients with acute exacer bation of asthma in the ED. In addition, the NIH NAEPP expert panel report 2 does not recommend the use of theophylline in children hospitalized with asthma or re ports that the addition of intravenous theophylline in hospitalized adults remains controversial. [11] However, recent literature examined the use of theophylline mainly in hospitalized children not responding to maximal treat ment (oxygen, inhaled bronchodilators, and glucocorticoids). A Cochrane review examined seven trials with a total of 380 participants. [25] All studies re cruited children with acute severe asthma requiring hos pital admission. Most of the patients were unresponsive to conventional therapy. The review showed that the addition of aminophylline significantly improved FEV1 and PEF percent-predicted; however, there was no sta tistical difference in the length of hospital stay, symp toms, frequency of nebulizations, or mechanical ventila tor rates. The most common side effect was vomiting. There was no significant difference in other side effects, which include hypokalemia, headaches, tremors, sei zures, arrythmias, and death. [25] Data to recommend the use of aminophylline in adults is lacking. The potential use of intravenous aminophylline is in patients with sta tus asthmaticus, resulting in respiratory failure, and is resistant to maximal conventional therapy. However, it is important to note that the administration of aminophyl line should be done by a clinician who is competent in dosing, monitoring serum levels, and assessing factors that modify clearance. Further research is needed to examine the role of aminophylline use in this extremely critical group of patients.
Magnesium Sulfate
Magnesium sulfate has been used as adjunct to stand ard therapy in patients with an acute exacerbation of asthma. Magnesium is a predominantly intracellular cation. Magnesium supplementation has been shown to cause bronchodilation. [26, 27] It is thought to produce this effect by inhibition of smooth muscle contraction through competitive antagonism with calcium; it may also be involved in acetylcholine and histamine release, in addition to possible role as an anti-inflammatory agent. Magnesium has been studied through either intravenous or inhalational administration. Rowe et al., in a review of the trials of intravenous magnesium sulfate in the treat ment of acute asthma in the ED, examined seven trials with a total of 668 patients treated. [28] The dose of mag nesium used in these trials was approximately 1-2 g. Magnesium was added to conventional therapy that in cluded β 2 -agonists and steroids. Although in the overall group, magnesium sulfate did not result in a reduction of hospital admissions, it was shown to be effective in reducing admission in the severe subgroup. Similarly, peak flow rate and FEV1 improved only in the patients with severe asthma exacerbation. In this study there were no significant changes in vital signs or side effects. How ever, magnesium may cause flushing and vasodilation, leading to transient hypotension. Therefore, although intravenous magnesium sulfate is not recommended for routine use in patients with acute asthma, it may have a role in the treatment of patient with severe asthma ex acerbation needing hospitalization and ICU care.
Inhaled magnesium sulfate has been studied in the treatment of acute asthma with variable results. A re cent systematic review of six trials (296 patients) was performed. [29] Four studies compared the addition of in haled MgSO 4 to nebulized albuterol and two studies com pared inhaled MgSO 4 alone to nebulized albuterol. The doses of inhaled magnesium were highly variable. The pooling of data showed a significant improvement in lung function, with no difference in the rate of hospitalization. This effect was more pronounced in the most severe cases.
Heliox
Helium is a colorless, odorless, non-inflammable gas discovered in 1968. Its medical use as a carrier gas for oxygen instead of nitrogen was first described by Barach in 1930. It was used mainly for treatment of respiratory failure owing to upper airway obstruction. Barach also used helium-oxygen mixture in the treatment of acute exacerbation of asthma; however, it fell out of favor af ter the advent of bronchodilators. [30] Helium has a very low density (0.43 g/l), which is one-seventh of the den sity of air. Owing to its low density, helium improves gas flow through high-resistance airways by increasing laminar flow. [31] Helium-oxygen mixtures can vary in the concentration of oxygen, depending on the level of hy poxia (80/20, 70/30, or 60/40). Heliox has been studied in the treatment of nonintubated acute asthma patients in several studies. Rodrigo et al. systematically exam ined the literature in a Cochrane review. Six randomized controlled trials were included, with a total of 369 pa tients. [32] Patients treated with Heliox did not show any improvement in pulmonary function. Heliox did not re duce the rate of hospital admission. It has also been studied in patients receiving mechanical ventilation. It was shown, in small studies, to improve oxygenation and respiratory acidosis, and decrease peak airway pres sures. [33] [34] [35] It is, however, important to note that helium can interfere in the measurement of pressure and vol ume during mechanical ventilation. Heliox has also been studied as a vehicle to carry bronchodilators distally into the lung. Bag et al. [36] and Kress et al. [37] have examined the role of Heliox as a driving gas for delivering the bron chodilator-both have shown improvements in FEV1. Kress et al. [37] randomized 45 patients to receive albuterol nebulized with either oxygen or heliox 80/20 as the driv ing gas. The treatment group (Heliox group) had signifi cantly larger improvement in FEV1 after each inhala tion.
Noninvasive Ventilation
Noninvasive ventilation has been shown to be effec tive in the treatment of hypercapneic respiratory failure secondary to acute exacerbation of chronic obstructive pulmonary disease. [38] Respiratory failure in acute exac erbation of asthma is thought to be similar to chronic obstructive pulmonary disease. A review of the litera ture revealed several studies examining the role of noninvasive ventilation in patients with acute exacerba tion of asthma. [39] Only one study was prospective, randomized, and controlled. [40] In this trial, Soroksky et al. randomized 30 patients with a severe asthma attack to bilevel positive pressure ventilation plus conventional therapy (N=15) and conventional therapy alone (N=15). Patient treated with noninvasive ventilation had a sig nificant improvement in FEV1 and a reduced rate of hospitalization. Although the use of noninvasive ventila tion in patients with acute exacerbation of asthma looks promising, further large, randomized trials are needed. Noninvasive ventilation has its limitations. It should only be used on awake and cooperative patients. Patients requiring airway protection and frequent suctioning as well as patients with facial trauma should not be treated with this modality.
Invasive Mechanical Ventilation Indications
The need for mechanical ventilation in patients pre senting with status asthmaticus varies considerably in the medical literature ranging from 2 to 70% with a mean of 31.8%. [41] The indications for intubation and mechani cal ventilation usually are progressive hypercapnia, obtundation, and impending cardiopulmonary collapse. Hypercapnia alone does not protend need for mechani cal ventilation. In a study by Mountain et al., [42] only 8% of patients presenting with hypercapnia required me chanical ventilation.
Endotracheal Intubation
Once intubation and mechanical ventilation have been deemed necessary, it is important not to delay the intu bation procedure and preferably perform the procedure electively under controlled conditions. [11, 43] Rapid se quence intubation should be performed by the most ex perienced operator to prevent bronchospasm. Bronchos pasm is best prevented by pretreatment with inhaled albuterol. Intravenous lidocaine has not been shown to attenuate intubation-induced bronchospasm. [44] The oral route is the preferred route for intubation in patients with status asthmaticus, as it allows the use of larger size endotracheal tubes, thereby decreasing airway resist ance and allowing better suctioning of secretions and mucous plugs. [43] Nasal intubation, however, can be per formed on conscious patients with minimal need for seda tives.
Sedation and Paralysis
Deep sedation and occasionally paralysis are required in patients with severe asthma on mechanical ventila tion. Deep sedation can be achieved with a variety of agents, including benzodiazipines, opiates, and propofol. Although morphine is inexpensive and provides adequate analgesia, it has been associated with worsening bron chospasm owing to histamine release from mast cells. Additionally, morphine causes significant decrease in gut motility, causes chest wall rigidity, and lacks the amnes tic effect provided by the benzodiazepines. [43, 45] Ketamine can also be used for sedation of patients with status asthmaticus. It has been shown to have an added effect of bronchodilation. [46] However, dysphoria, hallucination, and increased pulmonary secretions limit its use. [47] Propofol is an excellent agent for sedation in patients with respiratory failure secondary to asthma. Propofol provides the advantage of being short-acting, with a rapid onset of action and ease of titration. It has also been shown to reduce respiratory resistance. [48] Dis advantages of Propofol include hypertriglyceridemia, decreasing the seizure threshold, and causing hypoten sion if the patient has inadequate intravascular volume.
It may be occasionally necessary to supplement se dation with neuromuscular blockade. Neuromuscular blockers include depolarizing agents such as succinylcholine and nondepolarizing agents such as pancuronium, vecuronium, atracurium, and cisatracurium. Succinylcholine can be used for during induction of anesthesia to facilitate intubation and has been associated with prolonged paralysis in patients with pseudocholinesterase deficiency. Non-depolarizing agents on the other hand have been used for prolonged periods of time. Pancuronium and vecuronium are elimi nated by the liver and kidney and therefore caution is needed in case of decrease in liver or kidney function. [49] Neuromuscular blockers have been associated with pro longed muscle weakness requiring prolonged mechani cal ventilation. Although this effect can be seen solely with the use of neuromuscular blockers, most patients with status asthmaticus receive high-dose steroids, caus ing further muscle weakness. [50] In a retrospective co hort study, Leatherman et al. reviewed 107 patients with severe asthma needing mechanical ventilation. The in cidence of muscle weakness was highest in the group of patients that received the combination of neuromus cular blockers and steroids. There was no evidence of weakness in the group of patients that received steroids only. [51] Neuromuscular blockers that contain an aminosteroid nucleus are more likely to be associated with weakness. To reduce the risk of this devastating side effect, guidelines were suggested by Guntupalli et al. [45] In patients requiring paralytics, an attempt at using the lowest possible dose should be made by using neu romuscular stimulators; CPK (creatinine phosphokinase) levels should be monitored, and drug holidays and early withdrawal of the medication should be attempted.
Ventilatory Strategy
Expiratory airflow limitation and dynamic hyperinflation are the predominant pathophysiologic features in patients with status asthmaticus. Mechanical ventilation strate gies in these patients should be aimed at prolonging expiratory time, thereby reducing end-expiratory lung volume. Dynamic hyperinflation referred to as "auto-PEEP" occurs owing to several factors including in creased ventilatory requirements and prolonged expira tory time constant secondary to airflow obstruction owingg to inflammation and mucus plugging as well as premature closure of airways during exhalation. This results in significant increase in work of breathing and increased inspiratory threshold for initiation of a breath. [52] Dynamic hyperinflation can be suspected by findings of increased peak airway pressure as well as persistence of expiratory flow at the time of initiation of the second breath. It should also be suspected when the patient is unable to trigger the ventilator despite respiratory efforts, hemodynamic instability, or pulseless electrical activity (PEA).
[45] Figure 1 shows findings on respiratory wave forms, which suggest the presence of dynamic hyperin flation. As noted, peak airway pressure is elevated. Pla teau pressure which is measured at the end of inspira tion by applying an inspiratory hold is also elevated. When an occlusion maneuver is performed at end of expiration, "auto-peep" can be detected by the presence Mechanical ventilation can be performed by either vol ume-or pressure-controlled ventilation. Traditionally, volume-controlled ventilation with tidal volumes of 8-10 ml/kg, inspiratory flow rate of 80-100 l/min, and a square waveform have been recommended. [45] If dynamic hy perinflation is detected, then several maneuvers can be performed to reduce its occurrence. Reducing tidal vol ume, increasing peak flow rate, and reducing respira tory rate can all increase expiratory time and allow bet ter emptying of the lung. Tuxen et al., [53] however, were able to show that the effect of tidal volume changes on dynamic hyperinflation is of greater magnitude than changes in inspiratory flow rate. Similarly, reduction in respiratory rate can reduce dynamic hyperinflation; how ever, the magnitude of its effect is modest. [54] PEEP can be used in selected patients with asthma. Low levels of PEEP have been shown to improve expiratory flow re sistance as well as improving ventilator triggering and reducing work of breathing. [55] Mechanical ventilation strategies to reduce dynamic hyperinflation often result in hypoventilation and respiratory acidosis. Significant hypercapnea is well tolerated, [56] if necessary correction of the metabolic acidosis by adding a buffer can be achieved.
Complications of Mechanical Ventilation
The two most common complications of mechanical ventilation in patients with respiratory failure secondary to severe asthma are hypotension and barotrauma. Hy potension can develop owing to dynamic hyperinflation, positive pressure ventilation, pneumothorax, or sedation. PEA, previously known as EMD (Electro-mechanical dis sociation), can occur in patients who are aggressively ventilated. [57] If hypotension occurs secondary to dynamic hyperinflation, an expiratory pause or even disconnect ing the patient from the ventilator and allowing the lungs to empty, can result in improvement in blood pressure. Barotrauma, on the other hand, should be suspected if the patient develops sudden hypotension, hypoxia, or subcutaneous emphysema. Barotrauma can occur in up to 27% of patients and it correlates well with end-expira tory lung volumes. [58] It is also important to note that ven tilator-associated pneumonia can develop in this patient population and it carries a high morbidity and mortality.
Conclusion
Severe asthma management is complex and challeng ing. Careful assessment of these patients is needed to provide prompt and adequate treatment to reduce mor bidity and mortality in this young population. Although much has been done in this field, research is still needed to better understand the pathophysiology of this disease and to provide new and better treatment modalities.
